Trials / Conditions / Acute Myeloid Leukemia Post Cytotoxic Therapy

Acute Myeloid Leukemia Post Cytotoxic Therapy

14 registered clinical trials studyying Acute Myeloid Leukemia Post Cytotoxic Therapy — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Opt NCT07012044	National Cancer Institute (NCI)	Phase 1
Not Yet Recruiting	Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following NCT05554419	National Cancer Institute (NCI)	Phase 2
Recruiting	A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034	Solu Therapeutics, Inc	Phase 1
Recruiting	Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid NCT05554406	National Cancer Institute (NCI)	Phase 2
Recruiting	MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Tr NCT05564390	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leu NCT05146739	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin NCT04802161	National Cancer Institute (NCI)	Phase 2
Recruiting	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With NCT04726241	PedAL BCU, LLC	Phase 1 / Phase 2
Active Not Recruiting	BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Mye NCT04214249	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Mye NCT04284787	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Synd NCT03953898	National Cancer Institute (NCI)	Phase 2
Completed	Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Y NCT02642965	Children's Oncology Group	Phase 1 / Phase 2
Terminated	Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies NCT02381548	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia NCT01861314	National Cancer Institute (NCI)	Phase 1